A new rapid-acting insulin could offer benefits to diabetics who require insulin therapy to keep their blood sugars under control. This rapid-acting insulin called Viaject is absorbed into the bloodstream more quickly than regular insulin or Humalog (another rapid-acting insulin), which means it not only normalizes blood sugars quickly but has other benefits to diabetics as well.
The Benefits of Viaject: A Rapid-Acting Insulin Treatment
One of the major drawbacks of diabetic insulin therapy is it causes weight gain. Insulin is a hormone produced by the pancreas that escorts glucose into cells to be used as fuel – or stored in the liver as glycogen. It also helps cells take up fats and amino acids. When cells take up fat that they can’t use right away for energy, they store it as triglycerides – those ugly fat deposits that line hips, thighs, and tummies. This is unfortunate since many type 2 diabetics are already overweight or obese.
Viaject inulin treatment has the benefit of causing less weight gain than regular insulin. When researchers gave middle-aged diabetics either Viaject or regular insulin along with their regular diabetic therapy, the group taking Viaject gained only half the weight of those taking regular insulin. The hemoglobin A1c levels in both groups were similar.
Another Benefit of Viaject Insulin Therapy
Another problem diabetics who take regular insulin experience is hypoglycemia or low-blood sugar. When blood sugar levels in diabetics drop it can have life-threatening consequences – unless a diabetic gets sugar quickly. This is why most people with diabetes who take insulin carry around a sugar source at all times. Viaject is less likely than regular insulin to cause hypoglycemia. This adds an extra margin of safety for diabetics prone to hypoglycemia.
A Drawback to Viaject Insulin Therapy
One problem with Viaject is it causes more pain and discomfort at the injection site than regular insulin, but researchers have a new ph-neutral formulation that causes less irritation than the one used in these studies.
Viaject Rapid-Acting Insulin Therapy: The Bottom Line?
The developers of Viaject are currently seeking FDA clearance after completing several human studies showed this rapid-acting insulin to be safe and effective. When it reaches the market, it could be a better insulin alternative for diabetics prone to hypoglycemic episodes or weight gain.
Family Practice News. September 1, 2010. page 14.